Skip to main content
Delfa

← All trials/NCT06468748

WithdrawnPhase 4

The Effects of Semaglutide on Body Composition and Performance in Military Personnel

The Effects of a GLP-1R Agonist (the Drug Wegovy®) on Body Composition and Performance in Military Personnel

Asset

Semaglutide

Subcutaneous · GLP-1 agonist

Listed sites

1

Recruiting sites

-

Actual enrollment

-

Study population

Obesity / overweight

Eligibility highlights

•BMI ≥30

Primary endpoints

•Body weight, absolute change (kg)•Body composition•Physical Performance

Registered trial locations

Locations reported to ClinicalTrials.gov for this trial snapshot. Site count is not enrollment count; per-site enrollment is not available from source.

Identifiers

Registered as

NCT IDNCT06468748
Org study ID24-05H

Timeline

Milestones

Study first posted2024-06-21actual
Study start2024-08-01actual
Primary completion2025-03-27actual
Study completion2025-03-27actual
Last update posted2025-12-19actual

Assets

Investigational agents

Semaglutide

Who this study enrolls

Obesity / overweight

Who can enroll

Minimum age18 Years
SexAll
Healthy volunteersAccepted

Inclusion criteria

•Active-duty military personnel
•Age ≥ 18 years at the time of signing informed consent.
•Body mass index (BMI) ≥ 30 kg/m2 or ≥ 27 kg/m2 with the presence of at least one weight-related comorbid condition (e.g., hypertension, dyslipidemia, etc.)
•History of at least one self-reported effort to lose body weight.
•Ability to exercise ≥ 3x per week during the study.

Exclusion criteria

•Currently in Basic Combat Training, Advanced Individual Training, or One Station Unit Training, or equivalence in other military services.
•Current or history of Type 1 or Type 2 Diabetes, cardiovascular (e.g., heart disease, peripheral artery disease), musculoskeletal (e.g., myopathies), immune (e.g., lupus, asthma), gastrointestinal (e.g., irritable bowel syndrome, pancreatitis), neurological (e.g., dystonia), pulmonary (pulmonary fibrosis, COPD, lung cancer), or renal diseases (e.g., kidney diseases), and eating disorders (e.g., bulimia nervosa, anorexia nervosa).
•History of cholecystectomy
•Personal or family history of medullary thyroid carcinoma or those with multiple endocrine neoplasia type 2.
•Participants who are pregnant or breastfeeding, or those who may be pregnant or were pregnant in the last 12 months.
•Male and female participants who plan or will attempt to become pregnant or help conceive a child within two months of treatment.
•Inability to exercise ≥ 3x per week during the study.
•Currently taking or history of routine use of medications known to affect metabolism or performance (e.g., thiazide diuretics, oral steroids, testosterone replacement therapy, etc.).
•Self-reported change in body weight ≥ 5 kg within 90 days before screening.
•Treatment with any medication for the indication of obesity within 90 days before screening.
•Treatment with other orally administered medications such as sulfonylureas, sitagliptin, phenytoin, levothyroxine, albuterol, prednisone, and other drugs as identified during screening by the medical screening and staff.
•Current or previously suspected alcohol abuse (defined as Harmful Use by the World Health Organization), those who meet criteria for alcohol abuse disorder (as outlined in the DSM-5), or other substance abuse (i.e., the use of illegal drugs or the use of prescription or over-the-counter drugs for purposes other than those for which they are meant to be used, or in excessive amounts.
•History of major depressive disorder.
•Participants with implanted or external electrical devices (e.g., pacemakers).
•On a specialized diet (e.g., keto, intermittent fasting).
•Claustrophobia or difficulty breathing with a face mask.
•Known or suspected hypersensitivity to study product(s) or related products.

Endpoints (6)

What's being measured

Protocol endpoints and posted registry outcome measures, grouped into outcome categories. Composite endpoints show their component event types. Standard codes (LOINC, SNOMED CT) are shown where available.

Coverage by outcome category

Weight & body composition
3
Other clinical outcomes
2
Patient-reported / QoL
1

Weight & body composition

3 endpoints
Primary/protocol endpoint

Weight Loss

Time frame:24 weeks

Body weight, absolute change (kg)

change from baseline, improvement

Primary/protocol endpoint

Body composition

Time frame:24 weeks

percent change from baseline, improvement

Secondary/protocol endpoint

Weight Loss Maintenance

Time frame:76 weeks

Body weight, absolute change (kg)

change from baseline, improvement

Patient-reported / QoL

1 endpoint
Secondary/protocol endpoint

Eating habits and mediators of eating behavior

Time frame:76 weeks

change from baseline, improvement

Other clinical outcomes

2 endpoints
Primary/protocol endpoint

Physical Performance

Time frame:24 weeks

percent change from baseline, improvement

Other/protocol endpoint/low confidence

Bone

Time frame:76 weeks

change from baseline, improvement

Provenance

Sources

Trial identity, design, statusClinicalTrials.gov API v2
Snapshot dateJuly 6, 2026
Endpoint classificationDelfa endpoint taxonomy v2 (May 13, 2026)
Results tableno registry results posted yet

Trial facts come from public ClinicalTrials.gov records. Endpoint categories are Delfa's classification of those records, not a ClinicalTrials.gov field. All figures reflect the July 6, 2026 snapshot.